Incomplete abortion
Conditions
Interventions
Group A:Starting on the day of the initial consultation, Mifepristone 25mg was taken orally twice daily for 5 days. Subsequently, Estradiol tablets/Estradiol dienogest tablets (starting with Estradiol
Group B:On the day of the initial consultation, Mifepristone 25 mg was taken orally twice daily for 5 days. Subsequently, Estradiol tablets/Estradiol dihydrogesterone tablets (starting with Estradiol
Group C:Initial treatment on the day of the first visit: Mifepristone 25 mg orally twice daily for 5 days, followed by Estradiol tablets/estradiol dydrogesterone tablets 2/10 mg (starting with estradi
Group D:On the day of the initial consultation, Mifepristone 25 mg was taken orally twice daily for 5 days. Subsequently, Estradiol tablets/Estradiol-Dydrogesterone tablets (starting with Estradiol ta
Sponsors
Hangzhou Women's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) After abortion (medical abortion, vacuum aspiration, forceps evacuation, etc.), a follow-up ultrasound within 7 to 14 days indicates the presence of heterogeneous structures or slightly hyperechoic areas in the uterine cavity, with or without blood flow signals; 2) Positive for Human Chorionic Gonadotropin in blood.
Exclusion criteria
Exclusion criteria: 1) Vaginal bleeding exceeds the usual menstrual flow; 2) There is a potential risk of infection requiring surgical treatment; 3) Dysfunction of vital organs such as the heart, liver, and kidneys, as well as drug allergies or contraindications, especially allergy to misoprostol-like drugs that can cause laryngeal edema and severe allergic shock in serious cases; 4) Suspected ectopic pregnancy; 5) Cannot rule out gestational trophoblastic disease; 6) Patients unwilling to accept drug conservative treatment; 7) No follow-up conditions; 8) The investigator, after inquiring about the subject's medical history and relevant physical examinations, determines that due to various medical, psychological, social, occupational, or other conditions, the clinical study may be affected.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate (%) by 5-7 days after the first turning point.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in diameter of residual material in the uterine cavity.;Serum human chorionic gonadotropin level;Duration of vaginal bleeding; | — |
Countries
China
Contacts
Public ContactJunmiao Xu
Hangzhou Women's Hospital
Outcome results
None listed